Oral Administration of Meloxicam Suppresses Low-Dose Endotoxin Challenge-Induced Pain in Thoroughbred Horses.
Authors: Urayama Shuntaro, Tanaka Akane, Kusano Kanichi, Sato Hiroaki, Nagashima Tsuyoshi, Fukuda Ippei, Fujisawa Chihiro, Matsuda Hiroshi
Journal: Journal of equine veterinary science
Summary
# Editorial Summary Meloxicam's preferential inhibition of COX-2 over COX-1 makes it theoretically advantageous over non-selective NSAIDs like flunixin meglumine for managing systemic inflammation whilst minimising gastrointestinal side-effects, yet its efficacy in equine endotoxaemia had not been rigorously evaluated. Five Thoroughbreds received either oral meloxicam or placebo 60 minutes before low-dose lipopolysaccharide challenge in a crossover design, with researchers monitoring clinical parameters (temperature, heart rate, respiratory rate, behavioural pain scoring, and hoof wall thermography) and systemic inflammatory markers (TNF-α, cortisol, leukocyte counts) over 420 minutes. Meloxicam-treated horses demonstrated significantly lower pain scores at 60, 90, 120, and 180 minutes post-LPS challenge, with the most robust suppression at the 90-minute timepoint (P < 0.01), whilst systemic inflammatory markers and other clinical parameters remained unchanged between groups. These findings suggest meloxicam possesses genuine analgesic properties in endotoxaemia independent of systemic inflammatory suppression—a clinically relevant distinction from other NSAIDs—making it a potentially valuable option for managing pain associated with inflammatory conditions without the intestinal mucosal complications observed with non-selective inhibitors. Future work should evaluate meloxicam's performance in naturally occurring endotoxic conditions and determine optimal dosing windows for maximal pain relief.
Read the full abstract on PubMed
Practical Takeaways
- •Meloxicam may be a safer alternative to flunixin meglumine for managing pain during systemic inflammatory conditions, particularly given its reduced GI toxicity profile
- •Pre-treating with meloxicam 60 minutes before an inflammatory challenge provides measurable pain reduction, suggesting potential prophylactic value in high-risk situations
- •This COX-2 selective approach offers a pharmacological option that addresses pain without suppressing the broader inflammatory response, which may be beneficial for recovery
Key Findings
- •Meloxicam administered 60 minutes prior to LPS infusion significantly reduced pain scores at 90 minutes (P < 0.01) and 180 minutes (P < 0.05) compared to control
- •Meloxicam showed analgesic efficacy in a low-dose equine endotoxin model without significant effects on systemic inflammatory markers (TNF-α, cortisol, leukocyte counts)
- •COX-2 preferential inhibition by meloxicam demonstrated clinical benefit in acute inflammatory pain without the documented gastrointestinal side effects associated with non-selective NSAIDs like flunixin meglumine